The incorrect handling of Diskus inhalers in Chinese patients with chronic obstructive pulmonary disease (COPD) is not well documented.
Objective:
The present study was conducted to evaluate in detail the handling errors related to the Diskus device, and to elucidate the importance of educating COPD patients on the proper use of the device.
Methods:
A total of 384 COPD patients from a pulmonary clinic in China over a period of 5 years were included in the study. The compliance of COPD patients to the 13 discrete steps of Diskus usage were scored and analyzed by three measures: (1) On day 0, patients were given only a package insert on Diskus, and the handling error rate was assessed. Then the patients were given instruction on the 13-step Diskus procedure until they could demonstrate the proper technique. (2) On days 1, 2, and 3, the observation group was continuously educated on a 13-step procedure, and the percentage of patients who scored 100% for each step was recorded. The control group had no such training. (3) On days 10, 20, and 30, the percentage of all subjects correctly performing the Diskus 13-step inhalation procedure was assessed.
Results:
Incorrect handling techniques on Diskus usage were widely distributed among Chinese COPD patients. Step 8 (“Inhale forcefully from the beginning, slowly, deeply, and uniformly during the inspiratory phase until the lungs are full”) was the most commonly mishandled step (93.8%). The total score and individual step scores of the patients from the observation group were significantly improved during 3-day continuous education. There was also a significantly higher percentage of correctly performed steps in the observation group than in the control group upon assessment on day 10 (96.24% vs. 85.63%, respectively; p<0.01), day 20 (97.31% vs. 86.09%, respectively; p<0.01), and day 30 (98.19% vs. 87.39%, respectively; p<0.01).
Conclusion:
Handling errors of the Diskus 13-step inhalation procedure were commonly observed in Chinese COPD patients. Continuous educational interventions and regular supervision by health-care providers are therefore crucial for the optimum use of the Diskus inhaler.
Get full access to this article
View all access options for this article.
References
1.
Global Initiative for Obstructive Lung Disease (GOLD), National Heart Lung and Blood Institute, National Institutes of Health: GOLD report. Global strategy for diagnosis, management and prevention of COPD. National Institutes of Health, Bethesda, MD; 2009. Available at www.goldcopd.org. Accessed June18, 2013.
CromptonGK, BarnesPJ, BroedersM, CorriganC, CorbettaL, DekhuijzenR, DubusJC, MagnanA, MassoneF, SanchisJ, ViejoJL, and VoshaarT: The need to improve inhalation technique in Europe: a report from the Aerosol Drug Management Improvement Team. Respir Med., 2006; 100:1479–1494.
4.
GiraudV, and RocheN: Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J., 2002; 19:246–251.
5.
VirchowJC, CromptonGK, Dal NegroR, PedersenS, MagnanA, SeidenbergJ, and BarnesPJ: Importance of inhaler devices in the management of airway disease. Respir Med., 2008; 102:10–19.
6.
MelaniAS, BonaviaM, CilentiV, CintiC, LodiM, MartucciP, SerraM, ScichiloneN, SestiniP, AlianiM, and NeriM: Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med., 2011; 105:930–938.
7.
LavoriniF, MagnanA, DubusJC, VoshaarT, CorbettaL, BroedersM, DekhuijzenR, SanchisJ, ViejoJL, BarnesP, CorriganC, LevyM, and CromptonGK: Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med., 2008; 102:593–604.
8.
StoloffSW, StempelDA, MeyerJ, StanfordRH, and Carranza RosenzweigJR: Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol., 2004; 113:245–251.
9.
KhassawnehBY, Al-AliMK, AlzoubiKH, BatarsehMZ, Al-SafiSA, ShararaAM, and AlnasrHM: Handling of inhaler devices in actual pulmonary practice: metered-dose inhaler versus dry powder inhalers. Respir Care., 2008; 53:324–328.
10.
BurdonJ, DroszczW, JonesR, JohnstonPR, and TrowellSJ: Comparison of efficacy and ease of handling of salmeterol and terbutaline powder inhalers. Int J Clin Pract., 1998; 52:85–88.
11.
Serra-BatllesJ, PlazaV, BadiolaC, and MorejonE; Inhalation Devices Study Group: Patient perception and acceptability of multidose dry powder inhalers: a randomized crossover comparison of Diskus/Accuhaler with Turbuhaler. J Aerosol Med., 2002; 15:59–64.
12.
MolimardM, RaherisonC, LignotS, DepontF, AbouelfathA, and MooreN: Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med., 2003; 16:249–254.
13.
MaltonA, SumbyBS, and SmithIJ: A comparison of in vitro drug delivery from two multidose powder inhalation devices. Eur J Clin Res., 1995; 7:16.
14.
NielsenKG, AukIL, BojsenK, IfversenM, KlugB, and BisgaardH: Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children. Eur Respir J., 1998; 11:350–354.
15.
SumbyB, SlaterA, AtkinsPJ, and PrimeD: Review of dry powder inhalers. Adv Drug Deliv Rev., 1997; 26:51–58.
16.
SchlaeppiM, EdwardsK, FullerRW, and SharmaR: Patient perception of the Diskus inhaler: a comparison with the Turbuhaler inhaler. Br J Clin Pract., 1996; 50:14–19.
17.
National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics—2002. J Allergy Clin Immunol., 2002; 110:S141–S219.
18.
VestboJ, HurdSS, AgustíAG, JonesPW, VogelmeierC, AnzuetoA, BarnesPJ, FabbriLM, MartinezFJ, NishimuraM, StockleyRA, SinDD, and Rodriguez-RoisinR: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary. Am J Respir Crit Care Med., 2013; 187:347–365.
19.
RootmensenGN, van KeimpemaAR, JansenHM, and de HaanRJ. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J Aerosol Med Pulm Drug Deliv., 2010; 23:323–328.
20.
GalvinWF, DunnePJ, and KallstromTJ: A Patient's Guide to Aerosol Drug Delivery. American Association for Respiratory Care, Irving, TX; p. 52, 2010.
21.
DolovichMB, AhrensRC, HessDR, AndersonP, DhandR, RauJL, SmaldoneGC, and GuyattG: Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest., 2005; 127:335–371.
22.
BroedersME, SanchisJ, LevyML, CromptonGK, and DekhuijzenPN; ADMIT Working Group: The ADMIT series—issues in inhalation therapy. 2. Improving technique and clinical effectiveness. Prim Care Respir J., 2009; 18:76–82.
23.
EpsteinS, MaidenbergA, HallettD, KhanK, and ChapmanKR: Patient handling of a dry-powder inhaler in clinical practice. Chest., 2001; 120:1480–1484.
24.
BrocklebankD, RamF, WrightJ, BarryP, CatesC, DaviesL, DouglasG, MuersM, SmithD, and WhiteJ: Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess., 2001; 5:1–149.
25.
NimmoCJ, ChenDN, MartinusenSM, UstadTL, and OstrowDN: Assessment of patient acceptance and inhalation technique of a pressurized aerosol inhaler and two breath-actuated devices. Ann Pharmacother., 1993; 27:922–927.
26.
SchulteM, OsseiranK, BetzR, WenckerM, BrandP, MeyerT, and HaidlP: Handling of and preferences for available dry powder inhaler systems by patients with asthma and COPD. J Aerosol Med Pulm Drug Deliv., 2008; 21:321–328.
27.
EverardML, DevadasonSG, and Le SouefPN: Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir Med., 1997; 91:624–628.
28.
NewmanSP: Dry powder inhalers for optimal drug delivery. Expert Opin Biol Ther., 2004; 4:23–33.
29.
KhilnaniGC, and BangaA: Aerosol therapy. Indian J Chest Dis Allied Sci., 2008; 50:10.
30.
KesserKC, and GellerDE: New aerosol delivery devices for cystic fibrosis. Respir Care., 2009; 54:754–767; discussion 767–758.
31.
NewmanSP, PaviaD, GarlandN, and ClarkeSW: Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. Eur J Respir Dis Suppl., 1982; 119:57–65.
32.
HillerFC, MazumderMK, WilsonJD, RenningerRG, and BoneRC: Physical properties of therapeutic aerosols. Chest., 1981; 80:901–903.
33.
UsmaniOS, BiddiscombeMF, and BarnesPJ: Regional lung deposition and bronchodilator response as a function of β2-agonist particle size. Am J Respir Crit Care Med., 2005; 172:1497–1504.
34.
KhilnaniGC, and BangaA: Aerosol therapy. Indian J Chest Dis Allied Sci., 2008; 50:10.
35.
GlaxoSmithKline: Advair Diskus® 100/50 (fluticasone 100 mcg and salmeterol 50 mcg inhalation powder). Available at: www.advair.com. Accessed August8, 2012.
36.
LenneyJ, InnesJA, and CromptonGK: Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. Respir Med., 2000; 94:496–500.
37.
MelaniAS, ZanchettaD, BarbatoN, SestiniP, CintiC, CanessaPA, AiolfiS, and NeriM: Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann Allergy Asthma Immunol., 2004; 93:439–446.
38.
MelaniAS, BracciLS, and RossiM: Reduced peak inspiratory effort through the Diskus® and the Turbuhaler® due to mishandling is common in clinical practice. Clin Drug Investig., 2005; 25:543–549.
39.
NewmanSP: Aerosol deposition considerations in inhalation therapy. Chest., 1985; 88:152S–160S.
40.
LabirisNR, and DolovichMB: Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol., 2003; 56:588–599.
41.
LeachCL, and ColiceGL: A pilot study to assess lung deposition of HFA-beclomethasone and CFC-beclomethasone from a pressurized metered dose inhaler with and without add-on spacers and using varying breathhold times. J Aerosol Med Pulm Drug Deliv., 2010; 23:355–361.
42.
Schiller-ScotlandCF, GebhartJ, HochrainerD, and SiekmeierR: Deposition of inspired aerosol particles within the respiratory tract of patients with obstructive lung disease. Toxicol Lett., 1996; 88:255–261.
43.
McFaddenERJr: Improper patient techniques with metered dose inhalers: clinical consequences and solutions to misuse. J Allergy Clin Immunol., 1995; 96:278–283.
44.
ShimC, and WilliamsMHJr: The adequacy of inhalation of aerosol from canister nebulizers. Am J Med., 1980; 69:891–894.
45.
BrennanVK, OsmanLM, GrahamH, CritchlowA, and EverardML: True device compliance: the need to consider both competence and contrivance. Respir Med., 2005; 99:97–102.
46.
AllenSC, JainM, RagabS, and MalikN: Acquisition and short-term retention of inhaler techniques require intact executive function in elderly subjects. Age Ageing., 2003; 32:299–302.
47.
BarnesPJ, PedersenS, and BusseWW: Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med., 1998; 157:S1–S53.
48.
KestenS, EliasM, CartierA, and ChapmanKR: Patient handling of a multidose dry powder inhalation device for albuterol. Chest., 1994; 105:1077–1081.
49.
BerradeE, and TorreaS: [The handling of inhalers by bronchitis patients]. An Sist Sanit Navar., 1999; 22:81–85.
50.
Gracia-AntequeraM, and Morales Suarez-VarelaM: An intervention to improve the inhalatory technique of children and adolescents with asthma. Allergol Immunopathol (Madr)., 1999; 27:255–260.
51.
LaubeBL, JanssensHM, de JonghFH, DevadasonSG, DhandR, DiotP, EverardML, HorvathI, NavalesiP, VoshaarT, and ChrystynH: What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J., 2011; 37:1308–1331.
